Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Doering, K.
Right arrow Articles by Hassiepen, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Doering, K.
Right arrow Articles by Hassiepen, U.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A Fluorescence Lifetime-Based Assay for Protease Inhibitor Profiling on Human Kallikrein 7

Klaus Doering

26 South Street, Middle Barton, United Kingdom

Gabriele Meder

Novartis Institutes for BioMedical Research (NIBR), Expertise Platform Proteases, Novartis Pharma AG, Basel, Switzerland

Manuela Hinnenberger

Novartis Institutes for BioMedical Research (NIBR), Expertise Platform Proteases, Novartis Pharma AG, Basel, Switzerland

Julian Woelcke

Novartis Institutes for BioMedical Research (NIBR), Expertise Platform Proteases, Novartis Pharma AG, Basel, Switzerland

Lorenz M. Mayr

Novartis Institutes for BioMedical Research (NIBR), Expertise Platform Proteases, Novartis Pharma AG, Basel, Switzerland

Ulrich Hassiepen

Novartis Institutes for BioMedical Research (NIBR), Expertise Platform Proteases, Novartis Pharma AG, Basel, Switzerland, ulrich.hassiepen{at}novartis.com

Fluorescence lifetime is an intrinsic parameter describing the fluorescence process. Changes in the fluorophore's physicochemical environment can lead to changes in the fluorescence lifetime. When used as the readout in biological assays, it is thought to deliver superior results to conventional optical readouts. Hence it has the potential to replace readout technologies currently established in drug discovery such as absorption, luminescence or fluorescence intensity. Here we report the development of an activity assay for human kallikrein 7, a serine protease involved in skin diseases. As a probe, we have selected a blue-fluorescent acridone dye, featuring a remarkably long lifetime that can be quenched by either of the 2 natural amino acids, tyrosine and tryptophan. Incorporating this probe and 1 of the quenching amino acids on either side of the scissile bond of the substrate peptide enables us to monitor the enzymatic activity by quantifying the increase in the fluorescence lifetime signal. A systematic investigation of substrate structures has led to a homogenous, microplate-based, compound profiling assay that yields inhibitory constants down into the single-digit nanomolar range. This type of assay has now been added to our standard portfolio of screening techniques, and is routinely used for compound profiling. ( Journal of Biomolecular Screening 2009:1-9)

Key Words: compound profiling • high-throughput screening • fluorescence lifetime • compound interference • kallikrein 7

Journal of Biomolecular Screening, Vol. 14, No. 1, 1-9 (2009)
DOI: 10.1177/1087057108327328
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?